Active Ingredient History
Cixutumumab (IMC-A12) is a human monoclonal antibody for the treatment of solid tumors. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Adenocarcinoma of Lung (Phase 2)
Adrenocortical Carcinoma (Phase 2)
Brain Stem Neoplasms (Phase 1)
Breast Neoplasms (Phase 2)
Breast Neoplasms, Male (Phase 1/Phase 2)
Carcinoma (Phase 2)
Carcinoma, Hepatocellular (Phase 2)
Carcinoma, Merkel Cell (Phase 1)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Chondrosarcoma (Phase 1)
Colonic Neoplasms (Phase 2)
Colorectal Neoplasms (Phase 2)
Dermatofibrosarcoma (Phase 1)
Esophageal Neoplasms (Phase 2)
Fibrosarcoma (Phase 2)
Glioma (Phase 1)
Gliosarcoma (Phase 2)
Head and Neck Neoplasms (Phase 2)
Hepatoblastoma (Phase 2)
Leiomyosarcoma (Phase 2)
Leukemia, Mast-Cell (Phase 2)
Liposarcoma (Phase 2)
Liver Neoplasms (Phase 2)
Lung Neoplasms (Phase 2)
Lymphoma, Mantle-Cell (Phase 2)
Melanoma (Phase 2)
Mesothelioma (Phase 2)
Neoplasm Metastasis (Phase 2)
Neoplasms (Phase 1)
Nerve Sheath Neoplasms (Phase 2)
Neuroblastoma (Phase 2)
Neuroectodermal Tumors (Phase 2)
Neuroendocrine Tumors (Phase 2)
Osteosarcoma (Phase 2)
Pancreatic Neoplasms (Phase 2)
Paraganglioma (Phase 1)
Peritoneal Neoplasms (Phase 2)
Pinealoma (Phase 1)
Prostatic Neoplasms (Phase 2)
Rectal Neoplasms (Phase 2)
Retinoblastoma (Phase 2)
Rhabdomyosarcoma (Phase 2)
Sarcoma (Phase 2)
Sarcoma, Ewing (Phase 2)
Sarcoma, Synovial (Phase 2)
Small Cell Lung Carcinoma (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Thymoma (Phase 2)
Thyroid Neoplasms (Phase 1)
Wilms Tumor (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue